Earlier this week, FDA staffers recommended that Xarelto should not be marketed without more data, mainly because of questions about the controlgroup in its key study.
Because of the data already being collected about these people, the study allowed Saczynski's group to control for heart disease, heart attack, stroke, smoking, alcohol use and other factors that could have influenced dementia.